The Bacillus Calmette-Guérin (BCG) is a live attenuated tuberculosis vaccine that has the
ability to induce non-specific cross-protection against pathogens that might be unrelated to …

With 1.4 million deaths and 8.7 million new cases in 2011, tuberculosis (TB) remains a
global health care problem and together with HIV and Malaria represents one of the three …

Some species of the Mycobacterium tuberculosis complex (MTBC), particularly
Mycobacterium tuberculosis, which causes human tuberculosis (TB), are the first cause of …

ABSTRACT Mycobacterium bovis Bacille Calmette-Guérin (BCG) is the only licensed
vaccine against tuberculosis (TB), yet its moderate efficacy against pulmonary TB calls for …

Tuberculosis (TB) remains the deadliest infectious disease. The widely used bacille
Calmette–Guérin (BCG) vaccine offers only limited protection against TB. New vaccine …

Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …

Abstract Bacille Calmette–Guérin (BCG) vaccination can confer nonspecific protection
against heterologous pathogens. However, the underlying mechanisms remain mysterious …

A major challenge in tuberculosis (TB) is to improve current vaccination and therapeutic
strategies and this requires a fine understanding of the mechanisms that mediate protection …

Tuberculosis is a global threat to which infants are especially vulnerable. Effective vaccines
are required to protect infants from this devastating disease. VPM1002, a novel recombinant …

The tuberculosis (TB) pandemic continues to rampage despite widespread use of the BCG
(Bacillus Calmette–Guérin) vaccine. Novel vaccination strategies are urgently needed to …